Dihydropyrrolopyridine inhibitors of ROR-gamma
US9663515B2 · kind B2 · utility
12Cited by
25References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 5, 2015 |
| Grant date | May 30, 2017 |
| Priority date | — |
| Expiry date | Nov 5, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Provided are novel compounds of Formula (I):pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.